CHARGED ALPHA
Stock Analysis
Stock Library / FIZZ
FIZZ Unclassified Latest YouTube: FY2026

FIZZ

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

FIZZ Stock: The LaCroix Company Just Paid a Huge Special Dividend — Is It a Buy? (FY2026)

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
FY2026
Podcast available
Yes
Current price
$31.07
-1.18 (-3.66%)
Trailing / Forward P/E
15.85x
Forward: 15.13x
Market cap / Volume
Volume:
Revenue / Earnings Growth
-5.3%
Earnings: -8.5%
Margins
16.9% op
Gross: 37.0% · Net: 15.6%
Balance sheet
4.39x current
Debt / Equity: 9.3
52-week range / Beta
$30.01 - $47.85
Beta: 0.76
Analyst target
$33.00
Upside: 6.2%
Cash / shareholder return
3.65% FCF yield
Dividend yield: —

Company context

Industry: Beverages - Non-Alcoholic
Country: United States
Employees:
Price to book: 4.54x
Return on equity: 34.0%
National Beverage Corp., through its subsidiaries, develops, produces, markets, and sells a portfolio of sparkling waters, juices, energy drinks, and carbonated soft drinks in the United States and Canada. The company's Power+ brand portfolio offers sparkling water products under the LaCroix brands; non-carbonated water under the Clear Fruit; energy drink and shots under the Rip It brand; juice and juice-based products under Everfresh, Everfresh Premier Varietals, and Mr. Pure brands; and carbonated soft drinks under Shasta and Faygo brands. It serves retailers, as well as various smaller up-and-down-the-street accounts through the take-home, convenience, and food-service distribution channels. The company was incorporated in 1985 and is headquartered in Fort Lauderdale, Florida. National Beverage Corp. is a subsidiary of IBS Partners, Ltd.

Price chart

Market context for FIZZ

Competitive view

FIZZ vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

FIZZ latest YouTube video thumbnail YouTube
FIZZ
FIZZ
Latest video
FY2026
Growth profile looks mature or currently muted, which can cap multiple expansion unless execution improves.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
ADBE latest YouTube video thumbnail YouTube
ADBE
ADBE
Latest video
Q2 FY2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Abbott Laboratories latest YouTube video thumbnail YouTube
Abbott Laboratories
ABT
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
FIZZ
$2.91B
FIZZ
ADBE
$94.31B
ADBE
ABT
$175.37B
Abbott Laboratories
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
FIZZ
15.8x
FIZZ
ADBE
13.6x
ADBE
ABT
28.2x
Abbott Laboratories
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
FIZZ
15.1x
FIZZ
ADBE
8.6x
ADBE
ABT
16.6x
Abbott Laboratories
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
FIZZ
-5.3%
FIZZ
ADBE
12.7%
ADBE
ABT
7.8%
Abbott Laboratories
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
FIZZ
-8.5%
FIZZ
ADBE
7.9%
ADBE
ABT
-19.7%
Abbott Laboratories
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
FIZZ
16.9%
FIZZ
ADBE
35.3%
ADBE
ABT
13.5%
Abbott Laboratories
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
FIZZ
37.0%
FIZZ
ADBE
89.4%
ADBE
ABT
56.5%
Abbott Laboratories
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
FIZZ
15.6%
FIZZ
ADBE
28.7%
ADBE
ABT
13.9%
Abbott Laboratories
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
FIZZ
34.0%
FIZZ
ADBE
63.0%
ADBE
ABT
12.3%
Abbott Laboratories
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
FIZZ
3.6%
FIZZ
ADBE
9.8%
ADBE
ABT
3.6%
Abbott Laboratories
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
FIZZ
9.27x
FIZZ
ADBE
61.44x
ADBE
ABT
64.77x
Abbott Laboratories
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
FIZZ
4.39x
FIZZ
ADBE
0.75x
ADBE
ABT
1.39x
Abbott Laboratories
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
FIZZ
0.76
FIZZ
ADBE
1.43
ADBE
ABT
0.61
Abbott Laboratories
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
FIZZ
FIZZ
ADBE
ADBE
ABT
2.8%
Abbott Laboratories
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
FIZZ
6.2%
FIZZ
ADBE
14.8%
ADBE
ABT
15.8%
Abbott Laboratories

Related research

Non-quarter videos featuring FIZZ

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-07

FIZZ Stock: A $3.25 Special Dividend — Buy the LaCroix Maker? #Shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

Episode timeline

Episode archive for FIZZ

Each row is one earnings episode with every verified platform link available.

FY2026
Episode live
Published youtube podcast complete
FIZZ Stock: The LaCroix Company Just Paid a Huge Special Dividend — Is It a Buy? (FY2026)
Quarterly earnings-analysis entry for FIZZ. Use the links on the right to open the video or podcast episode.